A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review)
- Authors:
- Luca Falzone
- Giuseppa Scandurra
- Valentina Lombardo
- Giuseppe Gattuso
- Alessandro Lavoro
- Andrea Benedetto Distefano
- Giuseppe Scibilia
- Paolo Scollo
-
Affiliations: Epidemiology and Biostatistics Unit, National Cancer Institute‑IRCCS Fondazione G. Pascale, I‑80131 Naples, Italy, Medical Oncology Unit, Cannizzaro Hospital, I‑95126 Catania, Italy, Department of Biomedical and Biotechnological Sciences, University of Catania, I‑95123 Catania, Italy, Unit of Obstetrics and Gynecology, Cannizzaro Hospital, I‑95126 Catania, Italy - Published online on: June 14, 2021 https://doi.org/10.3892/ijo.2021.5233
- Article Number: 53
-
Copyright: © Falzone et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
|
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Falzone L, Salomone S and Libra M: Evolution of cancer pharmacological treatments at the turn of the third millennium. Front Pharmacol. 9:13002018. View Article : Google Scholar : PubMed/NCBI | |
|
Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A and Siegel RL: Ovarian cancer statistics, 2018. CA Cancer J Clin. 68:284–296. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Reid BM, Permuth JB and Sellers TA: Epidemiology of ovarian cancer: A review. Cancer Biol Med. 14:9–32. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Shafrir AL, Rice MS, Gupta M, Terry KL, Rosner BA, Tamimi RM, Hecht JL and Tworoger SS: The association between reproductive and hormonal factors and ovarian cancer by estrogen-α and progesterone receptor status. Gynecol Oncol. 143:628–635. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
D'Alonzo M, Bounous VE, Villa M and Biglia N: Current evidence of the oncological benefit-risk profile of hormone replacement therapy. Medicina (Kaunas). 55:5732019. View Article : Google Scholar | |
|
Craig ER, Londoño AI, Norian LA and Arend RC: Metabolic risk factors and mechanisms of disease in epithelial ovarian cancer: A review. Gynecol Oncol. 143:674–683. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Fenga C, Gangemi S, Di Salvatore V, Falzone L and Libra M: Immunological effects of occupational exposure to lead (Review). Mol Med Rep. 15:3355–3360. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Falzone L, Marconi A, Loreto C, Franco S, Spandidos DA and Libra M: Occupational exposure to carcinogens: Benzene, pesticides and fibers (Review). Mol Med Rep. 14:4467–4474. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Amir S, Shah STA, Mamoulakis C, Docea AO, Kalantzi OI, Zachariou A, Calina D, Carvalho F, Sofikitis N, Makrigiannakis A and Tsatsakis A: Endocrine disruptors acting on estrogen and androgen pathways cause reproductive disorders through multiple mechanisms: A review. Int J Environ Res Public Health. 18:14642021. View Article : Google Scholar : PubMed/NCBI | |
|
Ianoşi S, Ianoşi G, Neagoe D, Ionescu O, Zlatian O, Docea AO, Badiu C, Sifaki M, Tsoukalas D, Tsatsakis AM, et al: Age-dependent endocrine disorders involved in the pathogenesis of refractory acne in women. Mol Med Rep. 14:5501–5506. 2016. View Article : Google Scholar | |
|
Del Pup L, Mantovani A, Cavaliere C, Facchini G, Luce A, Sperlongano P, Caraglia M and Berretta M: Carcinogenetic mechanisms of endocrine disruptors in female cancers (Review). Oncol Rep. 36:603–612. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Rachoń D: Endocrine disrupting chemicals (EDCs) and female cancer: Informing the patients. Rev Endocr Metab Disord. 16:359–364. 2015. View Article : Google Scholar | |
|
Shulman LP and Dungan JS: Cancer genetics: Risks and mechanisms of cancer in women with inherited susceptibility to epithelial ovarian cancer. Cancer Treat Res. 156:69–85. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Gomes R, Spinola PD, Brant AC, Matta BP, Nascimento CM, de Aquino Paes SM, Bonvicino CR, Dos Santos AC and Moreira MA: Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients. Breast Cancer Res Treat. 185:851–861. 2021. View Article : Google Scholar | |
|
Hodgson A and Turashvili G: Pathology of hereditary breast and ovarian cancer. Front Oncol. 10:5317902020. View Article : Google Scholar : PubMed/NCBI | |
|
Jara L, Morales S, de Mayo T, Gonzalez-Hormazabal P, Carrasco V and Godoy R: Mutations in BRCA1, BRCA2 and other breast and ovarian cancer susceptibility genes in Central and South American populations. Biol Res. 50:352017. View Article : Google Scholar : PubMed/NCBI | |
|
Tedaldi G, Tebaldi M, Zampiga V, Danesi R, Arcangeli V, Ravegnani M, Cangini I, Pirini F, Petracci E, Rocca A, et al: Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer. Oncotarget. 8:47064–47075. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hanley GE, McAlpine JN, Miller D, Huntsman D, Schrader KA, Blake Gilks C and Mitchell G: A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention. BMC Cancer. 18:2542018. View Article : Google Scholar : PubMed/NCBI | |
|
Madariaga A, Lheureux S and Oza AM: Tailoring ovarian cancer treatment: Implications of BRCA1/2 mutations. Cancers (Basel). 11:4162019. View Article : Google Scholar | |
|
Ashour M and Ezzat Shafik H: Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome. Cancer Manag Res. 11:6275–6284. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tsaousis GN, Papadopoulou E, Apessos A, Agiannitopoulos K, Pepe G, Kampouri S, Diamantopoulos N, Floros T, Iosifidou R, Katopodi O, et al: Analysis of hereditary cancer syndromes by using a panel of genes: Novel and multiple pathogenic mutations. BMC Cancer. 19:5352019. View Article : Google Scholar : PubMed/NCBI | |
|
Nakonechny QB and Gilks CB: Ovarian cancer in hereditary cancer susceptibility syndromes. Surg Pathol Clin. 9:189–199. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Nishioka Y, Kobayashi K, Sagae S, Sugimura M, Ishioka S, Nagata M, Terasawa K, Tokino T and Kudo R: Mutational analysis of STK11 gene in ovarian carcinomas. Jpn J Cancer Res. 90:629–632. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
McLemore MR, Miaskowski C, Aouizerat BE, Chen LM and Dodd MJ: Epidemiological and genetic factors associated with ovarian cancer. Cancer Nurs. 32:281–288. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Faber MT, Kjær SK, Dehlendorff C, Chang-Claude J, Andersen KK, Høgdall E, Webb PM and Jordan SJ; Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group; et al Cigarette smoking and risk of ovarian cancer: A pooled analysis of 21 case-control studies. Cancer Causes Control. 24:989–1004. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Modugno F, Ness RB and Cottreau CM: Cigarette smoking and the risk of mucinous and nonmucinous epithelial ovarian cancer. Epidemiology. 13:467–471. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
O'Brien KM, Tworoger SS, Harris HR, Anderson GL, Weinberg CR, Trabert B, Kaunitz AM, D'Aloisio AA, Sandler DP and Wentzensen N: Association of powder use in the genital area with risk of ovarian cancer. JAMA. 323:49–59. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Fletcher NM, Harper AK, Memaj I, Fan R, Morris RT and Saed GM: Molecular basis supporting the association of talcum powder use with increased risk of ovarian cancer. Reprod Sci. 26:1603–1612. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Berge W, Mundt K, Luu H and Boffetta P: Genital use of talc and risk of ovarian cancer: A meta-analysis. Eur J Cancer Prev. 27:248–257. 2018. View Article : Google Scholar | |
|
Troisi R, Bjørge T, Gissler M, Grotmol T, Kitahara CM, Myrtveit Saether SM, Ording AG, Sköld C, Sørensen HT, Trabert B and Glimelius I: The role of pregnancy, perinatal factors and hormones in maternal cancer risk: A review of the evidence. J Intern Med. 283:430–445. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Havrilesky LJ, Moorman PG, Lowery WJ, Gierisch JM, Coeytaux RR, Urrutia RP, Dinan M, McBroom AJ, Hasselblad V, Sanders GD and Myers ER: Oral contraceptive pills as primary prevention for ovarian cancer: A systematic review and meta-analysis. Obstet Gynecol. 122:139–147. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Huang Z, Gao Y, Wen W, Li H, Zheng W, Shu XO and Beeghly-Fadiel A: Contraceptive methods and ovarian cancer risk among Chinese women: A report from the shanghai women's health study. Int J Cancer. 137:607–614. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Goff B: Symptoms associated with ovarian cancer. Clin Obstet Gynecol. 55:36–42. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Bankhead CR, Kehoe ST and Austoker J: Symptoms associated with diagnosis of ovarian cancer: A systematic review. BJOG. 112:857–865. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Rossing MA, Wicklund KG, Cushing-Haugen KL and Weiss NS: Predictive value of symptoms for early detection of ovarian cancer. J Natl Cancer Inst. 102:222–229. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kehoe S: FIGO staging in ovarian carcinoma and histological subtypes. J Gynecol Oncol. 31:e702020. View Article : Google Scholar : PubMed/NCBI | |
|
Tokunaga H, Shimada M, Ishikawa M and Yaegashi N: TNM classification of gynaecological malignant tumours, eighth edition: Changes between the seventh and eighth editions. Jpn J Clin Oncol. 49:311–320. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chua KJC, Patel RD, Trivedi R, Greenberg P, Beiter K, Magliaro T, Patel U and Varughese J: Accuracy in referrals to gynecologic oncologists based on clinical presentation for ovarian mass. Diagnostics (Basel). 10:1062020. View Article : Google Scholar | |
|
Barnes D, Rivera R, Gibson S, Craig C, Cragun J, Monk B and Chase D: The utility of patient reported data in a gynecologic oncology clinic. Gynecol Oncol Res Pract. 5:42018. View Article : Google Scholar : PubMed/NCBI | |
|
Funston G, Van Melle M, Baun ML, Jensen H, Helsper C, Emery J, Crosbie EJ, Thompson M, Hamilton W and Walter FM: Variation in the initial assessment and investigation for ovarian cancer in symptomatic women: A systematic review of international guidelines. BMC Cancer. 19:10282019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu JH and Zanotti KM: Management of the adnexal mass. Obstet Gynecol. 117:1413–1428. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Chan KK, Tam KF, Tse KY and Ngan HY: The role of regular physical examination in the detection of ovarian cancer recurrence. Gynecol Oncol. 110:158–161. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Scholler N and Urban N: CA125 in ovarian cancer. Biomark Med. 1:513–523. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Dochez V, Caillon H, Vaucel E, Dimet J, Winer N and Ducarme G: Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 12:282019. View Article : Google Scholar : PubMed/NCBI | |
|
Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Drescher CW, Paley P and Urban N: Use of a symptom index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol. 116:378–383. 2010. View Article : Google Scholar | |
|
Bastani A, Asghary A, Heidari MH and Karimi-Busheri F: Evaluation of the sensitivity and specificity of serum level of prostasin, CA125, LDH, AFP, and hCG+β in epithelial ovarian cancer patients. Eur J Gynaecol Oncol. 38:418–424. 2017. | |
|
Fischerova D and Burgetova A: Imaging techniques for the evaluation of ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 28:697–720. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
van Nagell JR Jr and Hoff JT: Transvaginal ultrasonography in ovarian cancer screening: Current perspectives. Int J Womens Health. 6:25–33. 2013. View Article : Google Scholar : | |
|
Zhang X, Meng X, Dou T and Sun H: Diagnostic accuracy of transvaginal ultrasound examination for assigning a specific diagnosis to adnexal masses: A meta-analysis. Exp Ther Med. 20:2652020. View Article : Google Scholar : PubMed/NCBI | |
|
Meng XF, Zhu SC, Sun SJ, Guo JC and Wang X: Diffusion weighted imaging for the differential diagnosis of benign vs. malignant ovarian neoplasms. Oncol Lett. 11:3795–3802. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Qiao JJ, Yu J, Yu Z, Li N, Song C and Li M: Contrast-enhanced ultrasonography in differential diagnosis of benign and malignant ovarian tumors. PLoS One. 10:e01188722015. View Article : Google Scholar : PubMed/NCBI | |
|
Sahdev A: CT in ovarian cancer staging: How to review and report with emphasis on abdominal and pelvic disease for surgical planning. Cancer Imaging. 16:192016. View Article : Google Scholar : PubMed/NCBI | |
|
Thabet A, Somarouthu B, Oliva E, Gervais DA, Hahn PF and Lee SI: Image-guided ovarian mass biopsy: Efficacy and safety. J Vasc Interv Radiol. 25:1922–1927.e1. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Khiewvan B, Torigian DA, Emamzadehfard S, Paydary K, Salavati A, Houshmand S, Werner TJ and Alavi A: An update on the role of PET/CT and PET/MRI in ovarian cancer. Eur J Nucl Med Mol Imaging. 44:1079–1091. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao C, Li S, Zhao M, Zhu H and Zhu X: Prognostic values of DNA mismatch repair genes in ovarian cancer patients treated with platinum-based chemotherapy. Arch Gynecol Obstet. 297:153–159. 2018. View Article : Google Scholar : | |
|
Hirotsu Y, Nakagomi H, Sakamoto I, Amemiya K, Oyama T, Mochizuki H and Omata M: Multigene panel analysis identified germline mutations of DNA repair genes in breast and ovarian cancer. Mol Genet Genomic Med. 3:459–466. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Missaoui N, Salhi S, Bdioui A, Mestiri S, Abdessayed N, Mokni M and Yacoubi MT: Immunohistochemical characterization improves the reproducibility of the histological diagnosis of ovarian carcinoma. Asian Pac J Cancer Prev. 19:2545–2551. 2018.PubMed/NCBI | |
|
Zlatian OM, Comănescu MV, Roşu AF, Roşu L, Cruce M, Găman AE, Călina CD and Sfredel V: Histochemical and immunohistochemical evidence of tumor heterogeneity in colorectal cancer. Rom J Morphol Embryol. 56:175–181. 2015.PubMed/NCBI | |
|
Docea AO, Mitruţ P, Grigore D, Pirici D, Călina DC and Gofiţă E: Immunohistochemical expression of TGF beta (TGF-β), TGF beta receptor 1 (TGFBR1), and Ki67 in intestinal variant of gastric adenocarcinomas. Rom J Morphol Embryol. 53(Suppl 3): S683–S692. 2012. | |
|
Lee JY, Kim S, Kim YT, Lim MC, Lee B, Jung KW, Kim JW, Park SY and Won YJ: Changes in ovarian cancer survival during the 20 years before the era of targeted therapy. BMC Cancer. 18:6012018. View Article : Google Scholar | |
|
Wu J, Sun H, Yang L, Deng Y, Yan Y, Wang S, Yang G and Ma H: Improved survival in ovarian cancer, with widening survival gaps of races and socioeconomic status: A period analysis, 1983-2012. J Cancer. 9:3548–3556. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Timmermans M, Sonke GS, Van de Vijver KK, van der Aa MA and Kruitwagen RF: No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands. Eur J Cancer. 88:31–37. 2018. View Article : Google Scholar | |
|
Nagle CM, Francis JE, Nelson AE, Zorbas H, Luxford K, de Fazio A, Fereday S, Bowtell DD, Green AC and Webb PM: Reducing time to diagnosis does not improve outcomes for women with symptomatic ovarian cancer: A report from the Australian ovarian cancer study group. J Clin Oncol. 29:2253–2258. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Engel J, Eckel R, Schubert-Fritschle G, Kerr J, Kuhn W, Diebold J, Kimmig R, Rehbock J and Hölzel D: Moderate progress for ovarian cancer in the last 20 years: Prolongation of survival, but no improvement in the cure rate. Eur J Cancer. 38:2435–2445. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Martín-Cameán M, Delgado-Sánchez E, Piñera A, Diestro MD, De Santiago J and Zapardiel I: The role of surgery in advanced epithelial ovarian cancer. Ecancermedicalscience. 10:6662016.PubMed/NCBI | |
|
Vinotha T, Anitha T, Ajit S, Rachel C and Abraham P: The role of completion surgery in ovarian cancer. J Obstet Gynaecol India. 66(Suppl 1): S435–S440. 2016. View Article : Google Scholar | |
|
Fagotti A, Perelli F, Pedone L and Scambia G: Current recommendations for minimally invasive surgical staging in ovarian cancer. Curr Treat Options Oncol. 17:32016. View Article : Google Scholar : PubMed/NCBI | |
|
Hall M, Savvatis K, Nixon K, Kyrgiou M, Hariharan K, Padwick M, Owens O, Cunnea P, Campbell J, Farthing A, et al: Maximal-effort cytoreductive surgery for ovarian cancer patients with a high tumor burden: Variations in practice and impact on outcome. Ann Surg Oncol. 26:2943–2951. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Shih KK and Chi DS: Maximal cytoreductive effort in epithelial ovarian cancer surgery. J Gynecol Oncol. 21:75–80. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Suh DH, Chang SJ, Song T, Lee S, Kang WD, Lee SJ, Roh JW, Joo WD, Yoon JH, Jeong DH, et al: Practice guidelines for management of ovarian cancer in Korea: A Korean society of gynecologic oncology consensus statement. J Gynecol Oncol. 29:e562018. View Article : Google Scholar : PubMed/NCBI | |
|
Kim SR, Kotsopoulos J, Sun P, Bernardini M, Laframboise S, Ferguson S, Rosen B, Narod SA and May T: The impacts of neoadjuvant chemotherapy and of cytoreductive surgery on ten-year survival from advanced ovarian cancer. Int J Gynaecol Obstet. 2017.Epub ahead of print. | |
|
Choi N, Chang JH, Kim S and Kim HJ: Radiation for persistent or recurrent epithelial ovarian cancer: A need for reassessment. Radiat Oncol J. 35:144–152. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Dowdy SC, Metzinger DS, Gebhart JB, Srivatsa P, Haddock MG, Suman VJ and Podratz KC: Salvage whole-abdominal radiation therapy after second-look laparotomy or secondary debulking surgery in patients with ovarian cancer. Gynecol Oncol. 96:389–394. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Shimada T, Saito T, Shimokawa M, Shimamoto K, Matsushita S, Yamaguchi S, Ariyoshi K and Okadome M: Improvement in the prognosis of ovarian cancer in the era before addition of molecular targeting therapy. Jpn J Clin Oncol. 47:494–498. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ledermann JA: First-line treatment of ovarian cancer: Questions and controversies to address. Ther Adv Med Oncol. 10:17588359187682322018. View Article : Google Scholar : PubMed/NCBI | |
|
Sato S and Itamochi H: Neoadjuvant chemotherapy in advanced ovarian cancer: Latest results and place in therapy. Ther Adv Med Oncol. 6:293–304. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chambers LM, Son J, Radeva M and DeBernardo R: Evaluation of non-completion of intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer. J Gynecol Oncol. 30:e932019. View Article : Google Scholar : PubMed/NCBI | |
|
Yoon JY, Koo YJ, Kim MJ, Kim TJ, Lim KT and Lee KH: Survival outcomes and toxicity of intraoperative intraperitoneal chemotherapy in advanced epithelial ovarian cancer. Obstet Gynecol Sci. 57:484–491. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL, DiSilvestro PA, Rubin SC, Martin LP, Davidson SA, et al: Weekly vs. Every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med. 374:738–748. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, et al: Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): A randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 15:396–405. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, Aoki D, Jobo T, Kodama S, Terauchi F, et al: Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): A randomised, controlled, open-label trial. Lancet Oncol. 14:1020–1026. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Marchetti C, Muzii L, Romito A and Benedetti Panici P: First-line treatment of women with advanced ovarian cancer: Focus on bevacizumab. Onco Targets Ther. 12:1095–1103. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Komiyama S, Kato K, Inokuchi Y, Takano H, Matsumoto T, Hongo A, Asai-Sato M, Arakawa A, Kamiura S, Tabata T, et al: Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: A prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial). Int J Clin Oncol. 24:103–114. 2019. View Article : Google Scholar | |
|
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, et al: A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 365:2484–2496. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, et al: Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 365:2473–2483. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Qian X, Qin J, Pan S, Li X, Pan Y and Ma S: Maintenance therapy in ovarian cancer with targeted agents improves PFS and OS: A systematic review and meta-analysis. PLoS One. 10:e01390262015. View Article : Google Scholar : PubMed/NCBI | |
|
Hess LM, Rong N, Monahan PO, Gupta P, Thomaskutty C and Matei D: Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: A meta-analysis. Cancer. 116:5251–5260. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Baert T, Ferrero A, Sehouli J, O'Donnell DM, González-Martín A, Joly F, van der Velden J, Blecharz P, Tan DSP, Querleu D, et al: The systemic treatment of recurrent ovarian cancer revisited. Ann Oncol. Mar 3–2021.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI | |
|
Lindemann K, Gao B, Mapagu C, Fereday S, Emmanuel C, Alsop K, Traficante N; Australian Ovarian Cancer Study Group; Harnett PR, Bowtell DDL and DeFazio A: Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. Gynecol Oncol. 150:239–246. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Guo B, Lian W, Liu S, Cao Y and Liu J: Comparison of diagnostic values between CA125 combined with CA199 and ultrasound combined with CT in ovarian cancer. Oncol Lett. 17:5523–5528. 2019.PubMed/NCBI | |
|
Mancari R, Cutillo G, Bruno V, Vincenzoni C, Mancini E, Baiocco E, Bruni S, Vocaturo G, Chiofalo B and Vizza E: Development of new medical treatment for epithelial ovarian cancer recurrence. Gland Surg. 9:1149–1163. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kozłowska E, Vallius T, Hynninen J, Hietanen S, Färkkilä A and Hautaniemi S: Virtual clinical trials identify effective combination therapies in ovarian cancer. Sci Rep. 9:186782019. View Article : Google Scholar | |
|
Burger RA, Sill MW, Monk BJ, Greer BE and Sorosky JI: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A gynecologic oncology group study. J Clin Oncol. 25:5165–5171. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Bamias A, Gibbs E, Khoon Lee C, Davies L, Dimopoulos M, Zagouri F, Veillard AS, Kosse J, Santaballa A, Mirza MR, et al: Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: Exploratory analyses of the AURELIA trial. Ann Oncol. 28:1842–1848. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Luvero D, Milani A and Ledermann JA: Treatment options in recurrent ovarian cancer: Latest evidence and clinical potential. Ther Adv Med Oncol. 6:229–239. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Dockery LE, Tew WP, Ding K and Moore KN: Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer. Gynecol Oncol. 147:509–513. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, et al: Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 33:244–250. 2015. View Article : Google Scholar | |
|
Lheureux S, Braunstein M and Oza AM: Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 69:280–304. 2019.PubMed/NCBI | |
|
Cortez AJ, Tudrej P, Kujawa KA and Lisowska KM: Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 81:17–38. 2018. View Article : Google Scholar : | |
|
Jiang X, Li W, Li X, Bai H and Zhang Z: Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer. Cancer Manag Res. 11:4371–4390. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, et al: Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 379:2495–2505. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Banerjee S, Gonzalez-Martin A, Harter P, Lorusso D, Moore KN, Oaknin A and Ray-Coquard I: First-line PARP inhibitors in ovarian cancer: Summary of an ESMO Open-Cancer Horizons round-table discussion. ESMO Open. 5:e0011102020. View Article : Google Scholar | |
|
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, et al: Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 381:2416–2428. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, et al: Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 381:2391–2402. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, et al: Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 18:1274–1284. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, et al: Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 375:2154–2164. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, et al: Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 15:852–861. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Balasubramaniam S, Beaver JA, Horton S, Fernandes LL, Tang S, Horne HN, Liu J, Liu C, Schrieber SJ, Yu J, et al: FDA approval summary: Rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer. Clin Cancer Res. 23:7165–7170. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Leonardi GC, Candido S, Falzone L, Spandidos DA and Libra M: Cutaneous melanoma and the immunotherapy revolution (Review). Int J Oncol. 57:609–618. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Vivarelli S, Falzone L, Grillo CM, Scandurra G, Torino F and Libra M: Cancer management during COVID-19 pandemic: Is immune checkpoint inhibitors-based immunotherapy harmful or beneficial? Cancers (Basel). 12:22372020. View Article : Google Scholar | |
|
Christofi T, Baritaki S, Falzone L, Libra M and Zaravinos A: Current perspectives in cancer immunotherapy. Cancers (Basel). 11:14722019. View Article : Google Scholar | |
|
Liu JF, Gordon M, Veneris J, Braiteh F, Balmanoukian A, Eder JP, Oaknin A, Hamilton E, Wang Y, Sarkar I, et al: Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol Oncol. 154:314–322. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Varga A, Piha-Paul S, Ott PA, Mehnert JM, Berton-Rigaud D, Morosky A, Yang P, Ruman J and Matei D: Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028. Gynecol Oncol. 152:243–250. 2019. View Article : Google Scholar | |
|
Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, et al: Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 33:4015–4022. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, et al: Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA. 105:3005–3010. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Zamarin D, Burger RA, Sill MW, Powell DJ Jr, Lankes HA, Feldman MD, Zivanovic O, Gunderson C, Ko E, Mathews C, et al: Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: An NRG oncology study. J Clin Oncol. 38:1814–1823. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Palaia I, Tomao F, Sassu CM, Musacchio L and Benedetti Panici P: Immunotherapy for ovarian cancer: Recent advances and combination therapeutic approaches. Onco Targets Ther. 13:6109–6129. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Chandra A, Pius C, Nabeel M, Nair M, Vishwanatha JK, Ahmad S and Basha R: Ovarian cancer: Current status and strategies for improving therapeutic outcomes. Cancer Med. 8:7018–7031. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Gotlieb WH, Amant F, Advani S, Goswami C, Hirte H, Provencher D, Somani N, Yamada SD, Tamby JF and Vergote I: Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: A phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 13:154–162. 2012. View Article : Google Scholar | |
|
McGee J, Bookman M, Harter P, Marth C, McNeish I, Moore KN, Poveda A, Hilpert F, Hasegawa K, Bacon M, et al: Fifth ovarian cancer consensus conference: Individualized therapy and patient factors. Ann Oncol. 28:702–710. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Aletti GD, Garbi A, Messori P, Achilarre MT, Zanagnolo V, Rizzo S, Alessi S, Bocciolone L, Landoni F, Biffi R, et al: Multidisciplinary approach in the management of advanced ovarian cancer patients: A personalized approach. Results from a specialized ovarian cancer unit. Gynecol Oncol. 144:468–473. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Pillay B, Wootten AC, Crowe H, Corcoran N, Tran B, Bowden P, Crowe J and Costello AJ: The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature. Cancer Treat Rev. 42:56–72. 2016. View Article : Google Scholar | |
|
Junor EJ, Hole DJ and Gillis CR: Management of ovarian cancer: Referral to a multidisciplinary team matters. Br J Cancer. 70:363–370. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Gleeson M, Meiser B, Barlow-Stewart K, Trainer AH, Tucker K, Watts KJ, Friedlander M and Kasparian N: Communication and information needs of women diagnosed with ovarian cancer regarding treatment-focused genetic testing. Oncol Nurs Forum. 40:275–283. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Stead ML, Brown JM, Fallowfield L and Selby P: Lack of communication between healthcare professionals and women with ovarian cancer about sexual issues. Br J Cancer. 88:666–671. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Selby P, Gillis C and Haward R: Benefits from specialised cancer care. Lancet. 348:313–318. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
August DA, Carpenter LC, Harness JK, Delosh T, Cody RL, Adler DD, Oberman H, Wilkins E, Schottenfeld D and McNeely SG: Benefits of a multidisciplinary approach to breast care. J Surg Oncol. 53:161–167. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Vinciguerra V, Degnan TJ, Sciortino A, O'Connell M, Moore T, Brody R, Budman D, Eng M and Carlton D: A comparative assessment of home versus hospital comprehensive treatment for advanced cancer patients. J Clin Oncol. 4:1521–1528. 1986. View Article : Google Scholar : PubMed/NCBI | |
|
Heudel PE, Devouassoux-Shisheboran M, Taieb S, Genestie C, Selle F, Morice P, Rouzier R and Ray-Coquard I: Multidisciplinary management of advanced ovarian cancer for an optimal therapeutic strategy. Eur J Gynaecol Oncol. 38:175–180. 2017.PubMed/NCBI | |
|
Bjørn SF, Schnack TH, Lajer H, Christensen IJ, Lundvall L, Thomsen LN and Høgdall C: Classification of ovarian cancer surgery facilitates treatment decisions in a gynecological multi-disciplinary team. Int J Gynecol Cancer. 27:382–389. 2017. View Article : Google Scholar | |
|
Pozzar RA and Berry DL: Patient-centered research priorities in ovarian cancer: A systematic review of potential determinants of guideline care. Gynecol Oncol. 147:714–722. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Moterani VC, Tiezzi DG, de Andrade JM and Candido Dos Reis FJ: Analysis of the relationship between hospital characteristics and survival in ovarian cancer: A historical cohort. J Surg Oncol. 122:1802–1807. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wright JD, Chen L, Hou JY, Burke WM, Tergas AI, Ananth CV, Neugut AI and Hershman DL: Association of hospital volume and quality of care with survival for ovarian cancer. Obstet Gynecol. 130:545–553. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Vernooij F, Heintz AP, Coebergh JW, Massuger LF, Witteveen PO and van der Graaf Y: Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in the Netherlands. Gynecol Oncol. 112:455–461. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Ke KM, Blazeby JM, Strong S, Carroll FE, Ness AR and Hollingworth W: Are multidisciplinary teams in secondary care cost-effective? A systematic review of the literature. Cost Eff Resour Alloc. 11:72013. View Article : Google Scholar : PubMed/NCBI | |
|
Mercado C, Zingmond D, Karlan BY, Sekaris E, Gross J, Maggard-Gibbons M, Tomlinson JS and Ko CY: Quality of care in advanced ovarian cancer: The importance of provider specialty. Gynecol Oncol. 117:18–22. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Long B, Chang J, Ziogas A, Tewari KS, Anton-Culver H and Bristow RE: Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California. Am J Obstet Gynecol. 212:468.e1–9. 2015. View Article : Google Scholar | |
|
Scott R, Hawarden A, Russell B and Edmondson RJ: Decision-making in gynaecological oncology multidisciplinary team meetings: A cross-sectional, observational study of ovarian cancer cases. Oncol Res Treat. 43:70–77. 2020. View Article : Google Scholar | |
|
Rausei S, Uccella S, D'Alessandro V, Gisone B, Frattini F, Lianos G, Rovera F, Boni L, Dionigi G and Ghezzi F: Aggressive surgery for advanced ovarian cancer performed by a multidisciplinary team: A retrospective analysis on a large series of patients. Surg Open Sci. 1:43–47. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Burton E, Chase D, Yamamoto M, de Guzman J, Imagawa D and Berman ML: Surgical management of recurrent ovarian cancer: The advantage of collaborative surgical management and a multidisciplinary approach. Gynecol Oncol. 120:29–32. 2011. View Article : Google Scholar | |
|
Forstner R, Meissnitzer M and Cunha TM: Update on imaging of ovarian cancer. Curr Radiol Rep. 4:312016. View Article : Google Scholar : PubMed/NCBI | |
|
Guerriero S, Saba L, Alcazar JL, Pascual MA, Ajossa S, Perniciano M, Piras A, Sedda F, Peddes C, Fabbri P, et al: Past, present and future ultrasonographic techniques for analyzing ovarian masses. Womens Health (Lond). 11:369–383. 2015. View Article : Google Scholar | |
|
Avril S: Histopathological markers of treatment response and recurrence risk in ovarian cancers and borderline tumors. Pathologe. 38(Suppl 3): S180–S191. 2017. View Article : Google Scholar | |
|
Rojas V, Hirshfield KM, Ganesan S and Rodriguez-Rodriguez L: Molecular characterization of epithelial ovarian cancer: Implications for diagnosis and treatment. Int J Mol Sci. 17:21132016. View Article : Google Scholar | |
|
Ramalingam P: Morphologic, immunophenotypic, and molecular features of epithelial ovarian cancer. Oncology (Williston Park). 30:166–176. 2016. | |
|
Lalwani N, Prasad SR, Vikram R, Shanbhogue AK, Huettner PC and Fasih N: Histologic, molecular, and cytogenetic features of ovarian cancers: Implications for diagnosis and treatment. Radiographics. 31:625–646. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kim H, Choi DH, Park W, Im YH, Ahn JS, Park YH, Nam SJ, Kim SW, Lee JE, Yu JH, et al: The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients: A large-scale study of Koreans. Hered Cancer Clin Pract. 17:12019. View Article : Google Scholar : PubMed/NCBI | |
|
Pruthi S, Gostout BS and Lindor NM: Identification and management of women with BRCA mutations or hereditary predisposition for breast and ovarian cancer. Mayo Clin Proc. 85:1111–1120. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Di Furia L, Rusciano MR, Nardini L, Rossi P, Giammarchi C, Vittori E, Tilocca S, Russo FL, Montuori P, Triassi M, et al: A nutritional approach to the prevention of cancer: From assessment to personalized intervention. Transl Med UniSa. 13:33–41. 2016.PubMed/NCBI | |
|
Zheng B, Shen H, Han H, Han T and Qin Y: Dietary fiber intake and reduced risk of ovarian cancer: A meta-analysis. Nutr J. 17:992018. View Article : Google Scholar : PubMed/NCBI | |
|
Crane TE, Khulpateea BR, Alberts DS, Basen-Engquist K and Thomson CA: Dietary intake and ovarian cancer risk: A systematic review. Cancer Epidemiol Biomarkers Prev. 23:255–273. 2014. View Article : Google Scholar : | |
|
Montagnese C, Porciello G, Vitale S, Palumbo E, Crispo A, Grimaldi M, Calabrese I, Pica R, Prete M, Falzone L, et al: Quality of life in women diagnosed with breast cancer after a 12-month treatment of lifestyle modifications. Nutrients. 13:1362020. View Article : Google Scholar | |
|
Porciello G, Montagnese C, Crispo A, Grimaldi M, Libra M, Vitale S, Palumbo E, Pica R, Calabrese I, Cubisino S, et al: Mediterranean diet and quality of life in women treated for breast cancer: A baseline analysis of DEDiCa multicentre trial. PLoS One. 15:e02398032020. View Article : Google Scholar : PubMed/NCBI | |
|
Hansen JM, Nagle CM, Ibiebele TI, Grant PT, Obermair A, Friedlander ML, DeFazio A and Webb PM; Ovarian Cancer Prognosis Lifestyle Study Group: A healthy lifestyle and survival among women with ovarian cancer. Int J Cancer. 147:3361–3369. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Thomson CA, E Crane T, Wertheim BC, Neuhouser ML, Li W, Snetselaar LG, Basen-Engquist KM, Zhou Y and Irwin ML: Diet quality and survival after ovarian cancer: Results from the women's health initiative. J Natl Cancer Inst. 106. pp. dju3142014, View Article : Google Scholar | |
|
Peres LC, Cushing-Haugen KL, Anglesio M, Wicklund K, Bentley R, Berchuck A, Kelemen LE, Nazeran TM, Gilks CB, Harris HR, et al: Histotype classification of ovarian carcinoma: A comparison of approaches. Gynecol Oncol. 151:53–60. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Jacome LS, Deshmukh SK, Thulasiraman P, Holliday NP and Singh S: Impact of COVID-19 pandemic on ovarian cancer management: Adjusting to the new normal. Cancer anag Res. 13:359–366. 2021. | |
|
Vivarelli S, Falzone L, Torino F, Scandurra G, Russo G, Bordonaro R, Pappalardo F, Spandidos DA, Raciti G and Libra M: Immune-checkpoint inhibitors from cancer to COVID-19: A promising avenue for the treatment of patients with COVID-19 (Review). Int J Oncol. 58:145–157. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Tsatsakis A, Calina D, Falzone L, Petrakis D, Mitrut R, Siokas V, Pennisi M, Lanza G, Libra M, Doukas SG, et al: SARS-CoV-2 pathophysiology and its clinical implications: An integrative overview of the pharmacotherapeutic management of COVID-19. Food Chem Toxicol. 146:1117692020. View Article : Google Scholar : PubMed/NCBI | |
|
Zimmerman BS, Seidman D, Berger N, Cascetta KP, Nezolosky M, Trlica K, Ryncarz A, Keeton C, Moshier E and Tiersten A: Patient perception of telehealth services for breast and gynecologic oncology care during the COVID-19 pandemic: A single center survey-based study. J Breast Cancer. 23:542–552. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Mancebo G, Solé-Sedeño JM, Membrive I, Taus A, Castells M, Serrano L, Carreras R and Miralpeix E: Gynecologic cancer surveillance in the era of SARS-CoV-2 (COVID-19). Int J Gynecol Cancer. 5:ijgc-2020–001942. 2020. | |
|
Frey MK, Ellis AE, Zeligs K, Chapman-Davis E, Thomas C, Christos PJ, Kolev V, Prasad-Hayes M, Cohen S, Holcomb K and Blank SV: Impact of the coronavirus disease 2019 pandemic on the quality of life for women with ovarian cancer. Am J Obstet Gynecol. 223:725.e1–725.e9. 2020. View Article : Google Scholar |
